Clinical Trial

LIBERTY: Liquid Biopsy to Diagnose and Monitor CNS Involvement in High-risk B Cell Non-Hodgkin Lymphoma

Study acronym: SAKK 38/23
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
Prevention and treatment of CNS relapse remains a great unmet clinical need in the management of aggressive B-NHL. Hence, investigating novel diagnostic tests is of paramount importance to improve risk-stratification of lymphoma patients at diagnosis, as is the evaluation of novel therapeutic approaches that may prevent and / or treat CNS recurrence. Based on the highlighted evidence, the investigators hypothesize that ctDNA detected within the CSF could potentially improve the detection rate of CNS involvement and consequently improve patients' stratification and better discriminate those in need of consolidative CNS prophylaxis on a molecular basis. Similarly, the investigators postulate that CSF ctDNA could be used as a monitoring tool to assess treatment response and guide therapeutic management.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2023-10-18; most recent amendment 2026-03-27.
Status change: Recruiting → Active, Not Recruiting 2026-03-27
Status change: Not Yet Recruiting → Recruiting 2024-03-13
Trial Details
NCT Number NCT06090162
Lead Sponsor Swiss Cancer Institute
Conditions Non-hodgkin Lymphoma, B Cell
Enrollment 64 participants
Start Date 2024-03-12
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-03-30